Navigation Links
GeneNews announces 2007 year end results
Date:3/26/2008

383

General and administrative 2,655,651 1,889,675

Stock-based compensation 478,172 728,383

Amortization of intellectual property 442,148 442,147

Foreign exchange loss 114,149 68,797

Interest on long-term debt 31,490 19,758

-------------------------------------------------------------------------

12,624,043 12,667,143

-------------------------------------------------------------------------

Interest income 822,286 448,202

-------------------------------------------------------------------------

Net and comprehensive loss for the year (9,634,045) (8,935,673)

Deficit, beginning of year (23,714,085) (14,778,412)

-------------------------------------------------------------------------

Deficit, end of year (33,348,130) (23,714,085)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Net and comprehensive loss per common share

Basic and fully diluted $(0.17) $(0.18)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average number of common

shares outstanding

Basic and fully diluted 55,453,018 49,045,966

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Note: The full financial statements with notes and auditors' report are

found on SEDAR

GeneNews Limited
'/>"/>

SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email: